Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer

Study ID
NCT00669370

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

GAST-TaxXel

Trial Summary

To determine the quality of life in patients with gastric cancer who receive combination treatment with docetaxel and capecitabine. Secondary endpoints are time to progression, overall response rate and overall survival. Study treatment will continue until disease progression or unacceptable toxicity.

More informations

Trial Starting Date

Jun 30,2006

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit